" class="no-js "lang="en-US"> LumiraDx Archives - Medtech Alert
Thursday, November 30, 2023

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that it has […]

LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 Ag Ultra […]

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing […]

LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals

Today, LumiraDx (Nasdaq: LMDX) a next-generation point of care (POC) diagnostics company announced that the intended use for its Food […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more